Combined archive search across FBI Vault, SPLC, PHMPT, ACIP, NIH grants, the Federal Writers' Project, and other collections we've ingested.
Nir Hacohen · BROAD INSTITUTE, INC. · 2023 · $221,595 — The development of scalable, cost-effective antibody libraries for detecting proteins (or other molecules) has greatly lagged the development of methods for detecting (e.g. by hybridization or sequencing) specific RNA or DNA sequences. If we were able to engineer antibodies against diverse targets a…
FREDERICK R BLATTNER · DNASTAR, INC. · 2023 · $1,000,000 — Therapeutic monoclonal antibodies bind to specific regions of proteins called epitopes, which elicit cellular responses that treat or cure disease. Discovering therapeutic antibodies traditionally requires costly and labor- intensive, laboratory-based screening experiments. Computational approaches …
Priyamvada Acharya · DUKE UNIVERSITY · 2023 · $683,445 — Structural characterization of Fab-dimerized glycan-reactive antibodies that neutralize HIV-1 A glycan shield covers the HIV-1 envelope (Env) limiting antibody access to broadly neutralizing antibody (bnAb) epitopes. 2G12 had for long been the only example of a HIV-1 bnAb that interacts solely with…
Peter Daszak · ECOHEALTH ALLIANCE, INC. · 2023 · $576,290 — Modified Project Summary/Abstract Section Zoonotic coronaviruses (CoVs) are a significant threat to global health, as demonstrated by the emergence of SARS, MERS, and COVID-19. Our group identified bats as the wildlife reservoirs of SARS-CoV, and we have now published hundreds of novel SARS-related…
Demonta Coleman · TEXAS A&M UNIVERSITY · 2023 · $38,073 — Project Summary The current cancer treatment bottleneck showcases the need for more innovative approaches in drug discovery efforts. As of recent, immune-checkpoint inhibitors (ICHs) have shown promise in cancer therapeutics, and work by manipulating immunoregulatory pathways involved in tumor detec…
Todd A Wyatt · OMAHA VA MEDICAL CENTER · 2023 — My primary research interests address chronic inflammatory lung disease, and the impact that behavioral and environmental exposures play in the compromise of lung innate defense against pathologic lung infections and injury. Utilizing pre-clinical mouse models and state-of-the-art molecular, biochem…
Ann Venables Griffith · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · 2023 · $193,750 — Summary The novel coronavirus, SARS-CoV-2, and the resulting Coronavirus Infectious Disease 2019 (COVID-19) has caused more than 500,000 deaths in the US. COVID-19 causes increased mortality and morbidity in patients over 65 years of age relative to younger patients. This is consistent with well-cha…
Deyu Fang · NORTHWESTERN UNIVERSITY AT CHICAGO · 2023 · $748,517 — Abstract Biomarker-guided treatment is key to improve outcomes of many diseases. The current COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a global crisis due to lagged vaccination and inefficient control of the virus, which has caused over 253 million c…
STEPHEN COPLAN HARRISON · BOSTON CHILDREN'S HOSPITAL · 2023 · $420,375 — Summary The structure of a virus particle must conform to the mechanism by which it enters and infects a cell. We seek to relate structures of virus particles and viral surface proteins to mechanisms of the steps in cell attachment, uptake and penetration that initiate a productive infection. The pr…
Yehia Mechref · TEXAS TECH UNIVERSITY · 2023 · $302,855 — Glycosylation is one of the most complex protein modifications; more than 50% of mammalian proteins are glycosylated. The fact that there are 100,000 proteoforms coded by only ~20,300 genes identified in the human genome emphasizes the importance of posttranslational modifications (PTMs) like glycos…
Magnus Adrian Gero Hoffmann · CALIFORNIA INSTITUTE OF TECHNOLOGY · 2023 · $421,000 — Project Summary/Abstract The COVID-19 pandemic represents the 3rd outbreak caused by zoonotic transmission of a beta-coronavirus (beta-CoV) in the last 20 years. Hence there is an urgent need for new vaccine strategies to control the ongoing pandemic and prevent future CoV outbreaks. mRNA vaccines h…
Matthew Reed Steinhart · INDIANA UNIVERSITY INDIANAPOLIS · 2023 · $2,500 — ABSTRACT Neurofibromatosis Type 2 (NF2) is a genetic condition in which specific types of tumors form in various locations throughout the body. Though the majority of these tumors grow slowly, the location of certain tumors can cause significant dysfunction. One of these tumor types grows on the ves…
Melody Y Zeng · WEILL MEDICAL COLL OF CORNELL UNIV · 2023 · $678,002 — Abnormal and potentially life-threatening blood clotting is seen in other severe infections, such as SARS- CoV-2, MERS, and H1N1 influenza. Platelets are produced by megakaryocytes. Enhanced megakaryopoiesis is found in severe COVID-19. Increased megakaryopoiesis is commonly found in autoimmune dise…
Joyce Jose · PENNSYLVANIA STATE UNIVERSITY, THE · 2023 · $236,286 — Mosquito-borne alphaviruses such as chikungunya, Mayaro, and Eastern equine encephalitis viruses cause high morbidity and mortality in their mammalian hosts. Alphaviruses are globally distributed arthropod-borne viruses that are enzootic in nature with the potential to disseminate to new geographica…
Milen Kirilov · INGENIOUS TARGETING LABORATORY, INC. · 2023 · $995,450 — Project Summary Genetically-modified mouse models have proven to be essential for the production of antibody-related biological drugs (biologics). To date, the majority of biologics originate from mouse models, and small animal models are used not only to generate the antibodies, but also as a platf…
Yicheng Tu · UNIVERSITY OF SOUTH FLORIDA · 2023 · $285,048 — Project Summary We will design and develop a molecular simulation data management system, we call P2DMS, to analyze large dis- tributed molecular dynamics (MD) simulation data. The salient features of the system include: (1) a push-based local query engine design that handles data in a batch process…
Vaughn Vasil Smider · APPLIED BIOMEDICAL SCIENCE INSTITUTE · 2023 · $967,225 — Abstract Targeted therapeutic agents range in size from very small organic molecules (100’s of Da) to protein-based molecules like monoclonal antibodies (~150,000 Da). Small disulfide bonded peptides have evolved in many species, including plants and animals, to have ideal pharmacological properties…
Matthew Reed Steinhart · INDIANA UNIVERSITY INDIANAPOLIS · 2023 · $55,194 — ABSTRACT Neurofibromatosis Type 2 (NF2) is a genetic condition in which specific types of tumors form in various locations throughout the body. Though the majority of these tumors grow slowly, the location of certain tumors can cause significant dysfunction. One of these tumor types grows on the ves…
Michael R. Farzan · UNIVERSITY OF FLORIDA · 2023 · $82,817 — Abstract The central hypothesis of this proposal is that the efficacy of mRNA vaccines that deliver membrane-anchored immunogens can be improved by localizing the immunogen to extracellular vesicles (EVs, small membrane- limited structures shed by eukaryotic cells). Our rationale is that EVs provide…
Goran Bajic · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2023 · $782,700 — Immunodominance, the observation that epitopes on an antigen are not “born equal”, poses a major challenge for next-generation vaccines against rapidly evolving pathogens. An underlying premise of this proposal is that in order to engage in rational immunogen design for next-generation vaccines, we …